GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Lenvatinib (LENVIMA)

Local RX List renal extractBase record retrieved 2026-09-07See the evidence for this drug2 sources available - open source summaries, references and comparisons

Lenvima

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
LENVIMA: severe-impairment instructions depend on indication

The severe-renal starting doses differ across thyroid, renal and endometrial cancer. The source supplies no corresponding severe-impairment HCC recommendation.

Before applying: Match indication and the actual-weight Cockcroft-Gault method; do not substitute another cancer indication's dose.

Also check: LENVIMA: severe-impairment instructions depend on indication

Rxlist source

GlobalRPh RX List - LENVIMA

Product / population
Lenvatinib - LENVIMA; selected renal source sections only, not a complete prescribing monograph.
Renal measure
Cockcroft-Gault creatinine clearance (CrCl), mL/min. Source specifies actual body weight.

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Renal dosing, restrictions and evidence limits

For severe renal impairment (CrCl <30 mL/min, Cockcroft-Gault using actual body weight), the source gives once-daily doses of 14 mg for differentiated thyroid cancer, 10 mg for renal cell carcinoma, and 10 mg for endometrial carcinoma. No renal dose adjustment is recommended in mild or moderate impairment. There is no recommended dose for hepatocellular carcinoma with severe impairment. Do not transfer one indication's dose to another or invent a dialysis schedule.

Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-08. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/lenvima-drug/

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

GlobalRPh RX List

GlobalRPh RX List - Lenvima

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Adult indication-specific oral dosing; do not exchange the renal doses between cancer indications.

Renal method: CrCl by Cockcroft-Gault using actual body weight, mL/min.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - LENVIMA

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Lenvatinib - LENVIMA; selected renal source sections only, not a complete prescribing monograph.

Renal method: Cockcroft-Gault creatinine clearance (CrCl), mL/min. Source specifies actual body weight.
Retrieved: 2026-09-08

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

LENVIMA: severe-impairment instructions depend on indication

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

indication scope

LENVIMA: severe-impairment instructions depend on indication

The severe-renal starting doses differ across thyroid, renal and endometrial cancer. The source supplies no corresponding severe-impairment HCC recommendation.

How to use this: Match indication and the actual-weight Cockcroft-Gault method; do not substitute another cancer indication's dose.

GlobalRPh RX List - LENVIMA

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeGlobalRPh RX List - LenvimaGlobalRPh RX List - LENVIMA
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/lenvima-drug/

Product and population scope

Adult indication-specific oral dosing; do not exchange the renal doses between cancer indications.

RDM33-SCOPE-lenvatinib-lenvima-C1 · Source section: Exact product identity and selected populationRenal section finder
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - Lenvima

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Adult indication-specific oral dosing; do not exchange the renal doses between cancer indications.

Renal method: CrCl by Cockcroft-Gault using actual body weight, mL/min.
Source date: Revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

No renal adjustment is recommended for CrCl 30 to 89 mL/min. For severe renal impairment, defined in the dose subsection as CrCl below 30 mL/min, the recommended daily dose is 14 mg for differentiated thyroid cancer, 10 mg for renal cell carcinoma, and 10 mg for endometrial carcinoma. No recommended severe-impairment dose is provided for hepatocellular carcinoma. End-stage renal disease has not been studied. Renal failure or impairment during treatment also requires severity-based withholding or discontinuation in the full label.

RDM33-rxlist-lenvatinib-lenvima-C1 · Source locator: Dosage modifications for severe renal impairment; use in specific populations: renal impairment.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/lenvima-drug/
Retrieved
2026-09-07
Renal-function method
CrCl by Cockcroft-Gault using actual body weight, mL/min.
Source date/version
Revision date not established in selected retrieval.
Hash meaning
SHA-256 of the local authored summary only; original HTML/PDF/SPL bytes are not bundled or hashed.
Local summary SHA-256
c7f6e7d3acb886147525d1b77e5b5492d147637a1ef13215255dc5ba8e9605e0
Rxlist

GlobalRPh RX List - LENVIMA

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Lenvatinib - LENVIMA; selected renal source sections only, not a complete prescribing monograph.

Renal method: Cockcroft-Gault creatinine clearance (CrCl), mL/min. Source specifies actual body weight.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-08

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

For severe renal impairment (CrCl <30 mL/min, Cockcroft-Gault using actual body weight), the source gives once-daily doses of 14 mg for differentiated thyroid cancer, 10 mg for renal cell carcinoma, and 10 mg for endometrial carcinoma. No renal dose adjustment is recommended in mild or moderate impairment. There is no recommended dose for hepatocellular carcinoma with severe impairment. Do not transfer one indication's dose to another or invent a dialysis schedule.

RDM47-rxlist-lenvatinib-lenvima-57e2780a65-C1 · Source locator: Severe renal dosage recommendations, lines 156-162; Use in Specific Populations: Renal Impairment.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/lenvima-drug/
Retrieved
2026-09-08
Renal-function method
Cockcroft-Gault creatinine clearance (CrCl), mL/min. Source specifies actual body weight.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
f73ed1da2a2ef6a0e642472ab8fc67c7bccbf2f9d0b1b73501f956143ef0d759

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 2 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/lenvima-drug/
Source retrieval
2026-09-07. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
45cfdab78227e6844e52f8535b15f6ed4f6a77ff4f97643cca5560e41d74b101
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report